An Extension Study of JR-141-BR21 in Patients With Mucopolysaccharidosis II
Status:
Active, not recruiting
Trial end date:
2026-12-31
Target enrollment:
Participant gender:
Summary
A Phase II open-label, parallel group, 2 sites (Brazil), designed to evaluate the long term
safety and efficacy of study drug for the treatment of the MPS II.